AstraZeneca PLC Q3 2026 Earnings Recap

AstraZeneca’s shares rose 7.0% after earnings, with investors responding to 7% revenue growth, 14% core EPS growth and a pipeline update that added more than $10 billion in non-risk-adjusted peak-sales potential. Growth was broad across key therapy areas, though Farxiga and Brilinta exclusivity losses and volume-based procurement in China remained headwinds.

Key Takeaways

• For the first nine months, total revenue grew 7% and core EPS increased 14%; revenue growth was 12% excluding Farxiga and Brilinta.
• Oncology, rare disease and respiratory & immunology delivered double-digit growth, more than offsetting expected headwinds from Farxiga and Brilinta losses of exclusivity and CVRM.
• China growth was affected by volume-based procurement; excluding that impact, revenue grew 13%, with growth across all therapy areas.
• The company reported positive results from 12 Phase III programs since February and first approvals for four new medicines, bringing approved new molecular entities to 14.
• Management cited more than $10 billion in non-risk-adjusted peak-year sales potential from positive pipeline readouts, while emphasizing continued investment toward its $80 billion revenue ambition for 2030.